Gentherapie

CRISPR/Cas9, ein revolutionäres Werkzeug zur Genbearbeitung, holds immense promise for correcting dystrophin deficiencies in Duchenne muscular dystrophy. By precisely targeting and modifying the DMD gene, CRISPR/Cas9 offers a potential therapeutic approach to restore dystrophin expression and alleviate the debilitating symptoms of this devastating disorder.

CRISPR/Cas9 emerges as a groundbreaking approach in cancer therapy, enabling precise targeting of oncogenic mutations. With its ability to disrupt cancer-driving genes, CRISPR/Cas9 offers hope for personalized and effective treatments, revolutionizing the future of cancer management.